title: [Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia].
abstract: OBJECTIVE
  The aim of this review is to discuss the negative effects on sexual function of medications for lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS-BPH).
  
  
  METHODS
  An international non-systematic literature review was performed. It included randomized trials of seven drugs of interest and the summaries of the characteristics of these products. This work did not aim comparison between the drugs.
  
  
  RESULTS
  Only maximal reported frequencies are presented in this abstract. With prolonged-release alfuzosin, they were 2.8% vs. 1.3% for erectile dysfunction, compared to placebo and 1% vs. 0% for ejaculatory dysfunction. With doxazosin, the incidence was 5.8% vs. 3.3% for erectile dysfunction, 3.6% vs. 1.9% for reduced libido and 0.4% vs. 1.4% for ejaculatory disorders. The incidence of ejaculatory disorders with tamsulosin, was 11% vs. <1% with the placebo and with silodosin, it was 28.1% vs. 1.1%. With finasteride, at 12 months, the highest frequency was 9% vs. 5% for erectile dysfunction, 4.4% vs. 1.5% for ejaculatory disorders and 6.4% vs. 3.4% for reduced libido. At 24 months, for dutatsteride, frequencies were 7.3% vs. 4.0% for erectile dysfunction, 2.2% vs. 0.8% for ejaculatory disorders and 4.2% vs. 2.1% for reduced libido. For tadalafil, a phosphodiesterase-5 inhibitor, and tolerodine, an anticholinergic drug, no negative effect on ejaculation or libido has been reported. For plant extracts, no sexual adverse effects (AEs) were reported among the most common AEs.
  
  
  CONCLUSIONS
  The medications for LUTS-BPH may alter erection, ejaculation or libido. A greater knowledge of the adverse effects of each of these drugs could guide physicians in the clinical management of men with BPH-LUTS.
authors.affiliation: Service de chirurgie urologique, CHU de Limoges, 87042 Limoges cedex, France. Electronic address: aureliendescazeaud@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Descazeaud
authors.affiliation: Service d'urologie, faculté de médecine de Créteil, groupe hospitalier Henri-Mondor, 94000 Créteil, France.
authors.forename: A
authors.initials: A
authors.lastname: de La Taille
authors.affiliation: Service de médecine physique et de réadaptation, faculté des sciences de la santé, université de Versailles Saint-Quentin en Yvelines, hôpital Raymond-Poincaré, 92380 Garches, France.
authors.forename: F
authors.initials: F
authors.lastname: Giuliano
authors.affiliation: Service d'urologie et de transplantation, hôpital Saint-Louis, université Paris 7, institut des maladies émergentes et des thérapies innovantes (iMETI), 75010 Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Desgrandchamps
authors.affiliation: 24, boulevard Vital-Bouhot, 92521 Neuilly-Sur-Seine cedex, France.
authors.forename: G
authors.initials: G
authors.lastname: Doridot
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced*
chemical_list: D000317:Adrenergic alpha-Antagonists
keywords: 5-alpha-reductase inhibitors; Alpha-blockers; Alpha-bloquants; Benign prostatic hyperplasia; Dysfonction érectile; Ejaculatory dysfunction; Erectile dysfunction; Hypertrophie bénigne de la prostate; Inhibiteurs de la 5-alpha-reductase; Inhibiteurs de la PDE5; Lower urinary tract symptoms; PDE5 inhibitors; Symptômes du bas appareil urinaire; Tadalafil; Troubles de l’éjaculation